FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Patterson Matthew R 		2. Issuer Name and Ticker or Trading Symbol

Audentes Therapeutics, Inc. [ BOLD ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

C/O AUDENTES THERAPEUTICS, INC., 600 CALIFORNIA STREET, 17TH FLOOR 		3. Date of Earliest Transaction (MM/DD/YYYY)

2/25/2019
(Street)

SAN FRANCISCO, CA 94108
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   2/25/2019     M (1)    17000   A $0.78   135700   D    
Common Stock   2/25/2019     S (1)    17000   D $30.00   118700   D    
Common Stock   2/25/2019     M (1)    4000   A $2.19   122700   D    
Common Stock   2/25/2019     S (1)    4000   D $30.00   118700   D    
Common Stock                  171814   I   By Matthew R. Patterson Revocable Trust   (2)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $0.78   2/25/2019     M   (1)       17000      (3) 9/25/2023   Common Stock   17000   $0.00   64751   (4) D    
Stock Option (right to buy)   $2.19   2/25/2019     M   (1)       4000      (5) 2/4/2025   Common Stock   4000   $0.00   74297   (4) D    

Explanation of Responses:
(1)  This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
(2)  The reporting person is the trustee of the Matthew R. Patterson Revocable Trust.
(3)  The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events.
(4)  The exercise of 26,901 options on July 3, 2018 and 23,147 options on July 5, 2018, each having an exercise price of $2.19 per share, were previously reported on Form 4 filed on July 5, 2018 as having an exercise price of $0.78. This Form 4 reflects the correct number of options attributed to each grant and beneficially owned following the transactions reported in this Form 4.
(5)  The option vested as to 25% of the total shares on February 4, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 4, 2019, subject to the reporting person's provision of service to the issuer on each vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Patterson Matthew R
C/O AUDENTES THERAPEUTICS, INC.
600 CALIFORNIA STREET, 17TH FLOOR
SAN FRANCISCO, CA 94108 		X
Chief Executive Officer

Signatures
/s/ Thomas Soloway as attorney-in-fact for Matthew Patterson 2/27/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Boundless Bio (NASDAQ:BOLD)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024 Boundless Bio 차트를 더 보려면 여기를 클릭.
Boundless Bio (NASDAQ:BOLD)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024 Boundless Bio 차트를 더 보려면 여기를 클릭.